Invuity Reports 2017 Third Quarter Financial Results SAN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
32
Invuity Reports 2017 Third Quarter Financial Results

SAN FRANCISCO, CA--(Marketwired - Nov 7, 2017) - Invuity, Inc. ( NASDAQ : IVTY ), a leading medical technology company focused on minimal access surgery, today reported financial results for the quarter ended September 30, 2017.

Q3 2017 Highlights

  • Revenue grew 13% to $9.6 million compared to revenue of $8.5 million in the third quarter of 2016.
  • Disposable revenue grew 17% to $7.5 million compared to $6.4 million in the third quarter of 2016.
  • Approximately 845 hospitals purchased Invuity devices in the third quarter of 2017, up from approximately 700 hospitals in the third quarter of 2016.
  • PhotonBlade full launch was completed in the third quarter of 2017.

"In the third quarter we made significant progress in broadening our offering of our high value surgical products. I am particularly excited about the full launch of PhotonBlade, and the early strong positive feedback from surgeons is very encouraging," said President and Chief Executive Officer Philip Sawyer. "Although sales were modestly impacted from hurricanes in the quarter, our continued growth underscores surgeons' confidence in our products that enable superior results in minimal access surgeries."

Financial Results

Revenue was $9.6 million in the third quarter of 2017, up 13% from revenue of $8.5 million in the third quarter of 2016 driven by an increase in active accounts. Management estimates that approximately $400,000 in revenue was lost due to the impact of hurricanes.

Gross margin for the third quarter was 69.9%. Gross margin was impacted by manufacturing overhead variances and to a lesser degree, early revenues from PhotonBlade and PhotonVue. Gross margin was 73.8% for the same period in 2016.

Total operating expenses for the third quarter were $15.1 million, compared to $14.6 million in the prior year period.

The net loss for the third quarter of 2017 was $8.9 million, or $0.52 loss per share, compared to a net loss of $8.8 million, or $0.56 loss per share, for the third quarter of 2016.

The Company's balance sheet as of September 30, 2017 included total cash, cash equivalents and short-term investments of $28.8 million.

Business Outlook

Invuity is narrowing its revenue guidance for 2017 to $40 million to $41 million.

Conference Call

Invuity's management will discuss the Company's financial results for the third quarter ended September 30, 2017, and provide a general business update during a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time today, November 7, 2017. To join the live call, participants may dial 1-877- 556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 3597539. To listen to the live call via Invuity's website, go to www.invuity.com , in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.

About Invuity®

Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's patented Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women's health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com .

Forward-Looking Statements

This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial projections for 2017. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.

 
INVUITY, INC.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
 
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2017     2016     2017     2016  
                                 
Revenue   $ 9,600     $ 8,478     $ 28,391     $ 23,106  
Cost of goods sold     2,888       2,219       8,002       6,416  
Gross profit     6,712       6,259       20,389       16,690  
Operating expenses:                                
  Research and development     2,326       2,471       7,165       7,412  
  Selling, general and administrative     12,790       12,134       41,847       38,885  
    Total operating expenses     15,116       14,605       49,012       46,297  
Loss from operations     (8,404 )     (8,346 )     (28,623 )     (29,607 )
Interest expense     (545 )     (505 )     (1,559 )     (1,514 )
Interest income     51       --       162       --  
Other income (expense), net     (9 )     30       (188 )     61  
Loss on extinguishment of debt     --       --       (2,303 )     --  
Net loss and comprehensive loss   $ (8,907 )   $ (8,821 )   $ (32,511 )   $ (31,060 )
Net loss per common share, basic and diluted   $ (0.52 )   $ (0.56 )   $ (1.91 )   $ (2.19 )
Weighted-average shares used to compute net loss per common share, basic and diluted     17,093,183       15,690,785       17,016,312       14,173,534  
                                 
 
Condensed Balance Sheets
as of September 30, 2017 and December 31, 2016
 (In thousands, except share and per share amounts)
(Unaudited)
 
  September 30,   December 31,  
  2017   2016  
Assets            
Current assets:            
  Cash and cash equivalents $ 24,338   $ 28,300  
  Short-term investments   4,497     10,737  
  Restricted cash - current   181     181  
  Accounts receivable, net   6,236     5,782  
  Inventory   6,496     5,052  
  Prepaid expenses and other current assets   1,634     1,088  
    Total current assets   43,382     51,140  
  Restricted cash   909     909  
  Property and equipment, net   7,430     8,286  
  Other long-term assets   333     --  
    Total assets $ 52,054   $ 60,335  
Liabilities and Stockholders' Equity            
Current liabilities:            
  Accounts payable $ 3,484   $ 2,192  
  Accrued and other current liabilities   5,934     6,351  
  Short-term debt   5,546     1,362  
    Total current liabilities   14,964     9,905  
Deferred rent   2,615     2,721  
Long-term debt   29,076     13,261  
    Total liabilities   46,655     25,887  
Commitments and contingencies (Note 8)            
Stockholders' equity:            
    Preferred stock, $0.001 par value--10,000,000 shares authorized at September 30, 2017 and December 31, 2016, no shares issued and outstanding at September 30, 2017 and December 31, 2016   --     --  
    Common stock, $0.001 par value--100,000,000 shares authorized at September 30, 2017 and December 31, 2016 17,123,856 and 16,950,940 shares issued and outstanding at September 30, 2017 and December 31, 2016   17     17  
  Additional paid-in capital   184,109     180,647  
  Accumulated deficit   (178,727 )   (146,216 )
Total stockholders' equity   5,399     34,448  
Total liabilities and stockholders' equity $ 52,054   $ 60,335  
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 246

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 53

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 60

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 70

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 125

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Sable Offshore Investors on Class Action

Updated Category News Views 261

Important Update for Sable Offshore Investors Sable Offshore Corp. (SOC), a prominent player in the oil transportation industry, is currently entangled in legal proceedings that have implications for its investors. If you've invested in SOC and suffered losses exceeding $100,000, there are critical updates you need to be aware of. Details on the Class Action Lawsuit A...

Continue Reading
Polestar Automotive Faces Lawsuit Over Financial Discrepancies

Updated Category News Views 353

Overview of the Legal Situation Concerning Polestar Automotive Recent events have brought attention to Polestar Automotive Holding UK PLC (NASDAQ: PSNY), a company known for its electric vehicles. A securities class action lawsuit has emerged, filed in the United States District Court for the District of New Jersey. This legal action is essential for individuals who...

Continue Reading
Quest Diagnostics' Q3 2024 Performance Boosts Annual Outlook

Updated Category News Views 257

Quest Diagnostics Reports Impressive Q3 2024 Financial Results Quest Diagnostics Incorporated (NYSE: DGX), a top provider of diagnostic information services, has shared its encouraging financial performance for the third quarter ended September 30, 2024. The company saw a notable increase in revenues, reaching $2.49 billion, representing an 8.5% rise compared to the...

Continue Reading
Castle Biosciences Receives NY Health Approval for TissueCypher

Updated Category News Views 118

Castle Biosciences Gains Approval for Revolutionary Test Castle Biosciences, Inc. (NASDAQ: CSTL), based in Friendswood, Texas, is charting a transformative course in healthcare with its recent approval from the New York State Department of Health for its TissueCypher Barrett’s Esophagus test. This achievement marks a significant milestone as TissueCypher stands out as...

Continue Reading
Oryzon Genomics to Conduct Insightful Virtual KOL Event

Updated Category News Views 147

Oryzon Genomics to Host Virtual KOL Event Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), renowned for its innovations in the field of epigenetics, has announced an engaging virtual KOL event aimed at addressing the complexities of Borderline Personality Disorder (BPD). This event, scheduled for a Wednesday at 12:00 pm ET, will be expertly moderated by Dr. Michael...

Continue Reading